Biotech – Pharma – Life sciences – Newsletter #64
|
Crowdfunding : MJN Neuroserveis – predicting epileptic seizures
|
- eTheRNA immunotherapies awarded €1M for its Production Process for TriMix mRNA Immunotherapies
- Cofactor Genomics announces $18M Funding to Bring RNA to Precision Medicine
- Medicago announces Phase 3 Study of VLP Quadrivalent Influenza Vaccine
- Lexogen – SLAMseq product : high-throughput metabolic sequencing of RNA
- Novel Milk-Derived Exosome Technology for Oral Administration of Nucleic Acids & Complex Small Molecules
- Natera selected for Circulating Tumor DNA Study in Bladder Cancer
- Medical Cannabis Companies Leverage Biosynthesis to Boost Drug Development
- MJN Neuroserveis – predicting epileptic seizures
- Biodegradable Plastics Needed to Increase Recycling Efficiency
- Biotech’s Leading the way in Life Altering Cancer Therapies
- Aspect Biosystems Closes First Round of Financing
- A leading Biopharma Supplier maximized Sales with the help of Digital Analytics
- Five-Year Survival for Newly Diagnosed Glioblastoma Patients
- Pharnext : Pivotal Phase 3 Trials of PXT3003 for Charcot-Marie-Tooth Disease Type 1A
- Next Generation Sequencing (NGS) Market – Growth, Trends & Forecasts 2016-2021
- Opdivo receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients
- $5.3M Agreement to Launch a New Plasma-Based Cancer Therapy Program